News

2026.10.28News Release

J-TEC and Maruho Enter into Sales Partnership Agreement for Autologous Cultured Epidermis Containing Melanocytes "JACEMIN"

2026.10.22Notification

Notice of Emergency Website Maintenance

2026.10.21News Release

Maruho and Incyte Enter into License Agreement for Ruxolitinib Cream in South Korea

2026.10.01News Release

Maruho Announces Out-Licensing Agreement for Hyperhidrosis Treatment (Topical Anticholinergic Agent) in the ASEAN Region

2026.06.08Notification

Executive Personnel Changes and New Executive Structure

2026.03.16Notification

Posted Activity Report "Maruho Report 2025" (English version)

2026.01.22News Release

Maruho Announces Out-Licensing Agreement for Hyperhidrosis Treatment (Topical Anticholinergic Agent) in Taiwan

2025.12.19Notification

Executive Personnel Changes and New Executive Structure

2025.11.17News Release

Maruho Announces Out-Licensing Agreement to China for Oral Penem Antibiotic (INN: Faropenem)

2025.11.04News Release

Maruho Enters a License Agreement with Nielsen BioSciences for the Treatment of Verruca Vulgaris (Common Warts) in Asia

2025.10.09News Release

Maruho Announces Exclusive Out-Licensing Agreement with Hyphens for In Vitro Diagnostic (Varicella-Zoster Virus Antigen Kit) in 10 ASEAN Countries

2025.10.01Notification

Maruho Co., Ltd. has deconsolidated Maruho Hatsujyo Kogyo Co., Ltd.​

2025.09.30News Release

Maruho Announces Strategic minority Investment in Sibel Health

2024.07.01News Release

Maruho and Sibel Health Enter into a Worldwide Collaborative Development and Commercialization Agreement for a New Digital Health Technology for Itch

2024.06.11News Release

Maruho Launches "Mitchga Subcutaneous Injection 30mg Vials", an Antibody Treatment for Pruritus Associated with Atopic Dermatitis (Pediatric) and Prurigo Nodularis in Japan

2024.06.05News Release

Maruho and Hyphens Pharma Announce Exclusive License Agreement for Anti-herpes Virus Agent (INN: Amenamevir) in 10 ASEAN Countries